Alcobra Ltd. (ADHD) Cut to Hold at Zacks Investment Research

Alcobra Ltd. (NASDAQ:ADHD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. “

Several other brokerages also recently issued reports on ADHD. WBB Securities upgraded Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Monday. Roth Capital downgraded Alcobra from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $4.00 to $1.00 in a report on Friday, September 29th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. Alcobra presently has an average rating of “Hold” and an average target price of $1.56.

Shares of Alcobra (NASDAQ ADHD) traded up 0.459% during midday trading on Wednesday, reaching $1.095. The company’s stock had a trading volume of 588,015 shares. The company’s market cap is $30.18 million. Alcobra has a 12 month low of $0.83 and a 12 month high of $2.68. The stock has a 50-day moving average of $1.06 and a 200 day moving average of $1.11.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts predict that Alcobra will post ($0.77) earnings per share for the current fiscal year.

WARNING: This report was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/11/alcobra-ltd-adhd-cut-to-hold-at-zacks-investment-research.html.

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC boosted its position in shares of Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after buying an additional 101,514 shares during the period. Worth Venture Partners LLC boosted its position in shares of Alcobra by 35.6% during the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after buying an additional 71,465 shares during the period. Finally, Royce & Associates LP boosted its position in shares of Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after buying an additional 100,000 shares during the period. 29.68% of the stock is owned by institutional investors.

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

NASDAQ ADHD) traded up 0.459% during midday trading on Wednesday, reaching $1.095. The company’s stock had a trading volume of 588,015 shares. The company’s market cap is $30.18 million. Alcobra has a 12 month low of $0.83 and a 12 month high of $2.68. The stock has a 50-day moving average of $1.06 and a 200 day moving average of $1.11.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts predict that Alcobra will post ($0.77) earnings per share for the current fiscal year.

WARNING: This report was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/11/alcobra-ltd-adhd-cut-to-hold-at-zacks-investment-research.html.

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC boosted its position in shares of Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after buying an additional 101,514 shares during the period. Worth Venture Partners LLC boosted its position in shares of Alcobra by 35.6% during the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after buying an additional 71,465 shares during the period. Finally, Royce & Associates LP boosted its position in shares of Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after buying an additional 100,000 shares during the period. 29.68% of the stock is owned by institutional investors.

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply